Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy

Figure 5

Effect of combining ASP7657 with anti-PD-1 antibody in CT26.WT or radiotherapy in the 4T1-ova model. (a, b) CT26.WT cells were inoculated ( cells per mouse) into the right flank of BALB/c mice ( per group). After tumors were established, mice were treated with ASP7657 twice per day at 3 mg/kg/day and with an anti-mPD-1 antibody or isotype control at 0.1 mg/head twice per week. Data show . , , compared with each single agent group (Student’s -test). (c, d) 4T1-ova cells were inoculated ( cells per mouse) into the right mammary fat pad of BALB/c mice ( per group). After tumors were established, mice were treated with ASP7657 twice per day at 1 or 3 mg/kg/day and irradiated with 5 Gy X-rays on days 0, 3, and 6. Data show . , compared with the ASP7657+sham radiation group (Student’s -test); ^#, ^##, compared with the vehicle+radiation group (Dunnett’s multiple comparison test).

(a)

(b)

(c)

(d)